Viatris vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Viatris (VTRS) reported ~$15.4B revenue in FY2024. Global generic and specialty pharmaceutical company formed by Pfizer's Upjohn spinoff merging with Mylan. HQ: Canonsburg, PA.
About
Viatris Inc. is a global pharmaceutical company formed in 2020 through the combination of Pfizer's off-patent branded drug unit (Upjohn) and Mylan, one of the world's largest generic drug manufacturers. The company manufactures, licenses, and distributes approximately 1,400 approved molecules across branded generics, complex generics, and a portfolio of iconic off-patent brands including Lipitor (atorvastatin), Viagra (sildenafil), EpiPen, and Xanax (alprazolam) sold in markets where these brands retain meaningful recognition and premium pricing.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.